Suven has a total of 18 granted patents from Australia and 12 from Eurasia
Hyderabad-based biopharmaceutical company Suven Life Sciences has announced that it has secured two patent approvals, one each from Australia and Eurasia for its new chemical entities (NCEs). They are to be used in the treatment of neurodegenerative diseases like Alzheimer's disease, Schizophrenia and Parkinson's disease.
These patents are valid until 2030 and 2029 respectively, the company said in a BSE filing.
The company's CEO Mr Venkat Jasti said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medial needs, and with huge market potential globally."
With these new patents, Suven has a total of 18 granted patents from Australia and 12 from Eurasia.
"These patents are exclusive intellectual property of Suven products. Any of these inventions may be out-licensed at various phases of clinical development like at Phase-1 and Phase-2," the company said.
